- 4009 Hackney Springs Ln, Sachse, TX 75048
How to spot silent revenue leakage before it shows up on your next P&L
Most labs don’t lose revenue in one dramatic moment. There’s no single bounced check, no billing partner who vanishes overnight. It happens in small, quiet increments; a denied claim that never gets appealed, a payer contract that hasn’t been renegotiated in three years, a report you have to ask for instead of one that lands in your inbox automatically. By the time it shows up on your P&L, you’ve usually been bleeding cash for months.
If you’re a lab owner, CFO, or operations director, you already know billing is complicated. What you may not know is whether your current partner is actually optimizing that complexity in your favor, or just processing claims and hoping for the best. Whether you handle billing in-house or outsource laboratory RCM services, here are five signs worth taking seriously and working on fixes to protect your claims.
A denial rate under 5% is achievable for most labs with disciplined front-end processes. Anything north of 10% usually points to a systemic problem, not a run of bad luck. The real test isn’t the number itself, though. It’s whether your billing partner can break that number down for you.
Ask your current partner this: of your denials last quarter, how many were CO-16 (missing information), how many were medical necessity denials tied to LCD coverage, and how many were duplicate claim rejections? If the answer is vague, or if it takes them a week to pull that data, that’s the sign. A partner who’s actually managing your revenue cycle can name your top three denial reasons off the top of their head, because they’re the ones fixing the upstream cause, not just refiling the same claim and hoping it clears the second time.
Cash flow problems in laboratory billing rarely start with a payer refusing to pay. They start with claims that sit untouched in a queue. Industry benchmarks put well-managed labs at 35 to 40 days in A/R. Once that number drifts past 45 and keeps climbing, you’re not looking at a slow payer; you’re looking at a billing team that isn’t working the aging report aggressively enough.
Here’s the part that gets missed: every extra week a claim sits in A/R is a week closer to timely filing deadlines, and a week further from a patient or payer actually remembering the details of the encounter. Old claims are harder claims. If your partner’s aging buckets past 90 days are growing instead of shrinking, that’s money that’s about to become uncollectible, not just late.
Molecular diagnostics, PLA codes, and MolDX-covered tests don’t bill like a routine chemistry panel, and they shouldn’t be handled like one. If your lab runs any genetic or molecular testing and your billing partner isn’t actively managing DEX Z-code registration, tracking MolDX LCD updates by MAC jurisdiction, and building payer-specific documentation checklists, you are almost certainly leaving reimbursement on the table.
This is one of the most common gaps we see when labs bring their billing in-house or work with a generalist RCM vendor. A biller who’s excellent with standard CPT and HCPCS coding can still be completely out of their depth on Z-code assignment or LDT-specific medical necessity requirements. The result isn’t usually an outright denial; it’s underpayment, which is much harder to spot because the claim technically “paid.”
If getting visibility into your own revenue cycle requires an email and a two-day wait, that’s a structural problem, not an inconvenience. A billing partner that’s genuinely invested in your growth gives you a live dashboard showing clean claim rate, denial rate by payer, A/R aging, and net collection rate, which is updated regularly and tied directly into your LIS or LIMS, not reconstructed from memory once a quarter.
Proactive reporting isn’t a nice-to-have. It’s the difference between catching a payer’s silent policy change in week two versus discovering it in month four, after fifty claims have already been denied the same way. If you can’t see the trend line, you can’t act on it.
A high clean claim rate looks great in a monthly summary. But clean claim rate only measures whether a claim was accepted on first submission; it says nothing about whether it was accepted at the correct reimbursement level, or whether the underwriting logic behind that acceptance actually favored your lab. Some billing partners optimize for the metric instead of the money: they’ll code conservatively to avoid a denial, even when a more complete, well-documented claim would have paid at a higher rate.
The real question isn’t just “did the claim get paid?” It’s “did it get paid what it should have, and is someone auditing underpayments the same way they audit denials?” If your partner treats a paid claim as a closed case rather than a data point, you’re likely losing money you’ll never see flagged anywhere.
At TransLabs, we built our billing operation specifically around the complexity labs deal with, like MolDX and DEX Z-code registration, LCD/NCD tracking by MAC jurisdiction, payer-specific documentation requirements, and a denial management process that treats every rejection as a pattern to fix, not a claim to resubmit and forget. Our clients get live dashboards, not quarterly summaries, and a team that can tell you your top three denial reasons without opening a spreadsheet.
If any of the five signs above sounded familiar, it’s worth finding out exactly where your revenue is leaking before it costs you another quarter.